Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Ulcerative Colitis
Interventions: Visilizumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Savannah, Georgia • Worcester, Massachusetts • Manhasset, New York + 2 more

Conditions: Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: cisplatin, cyclophosphamide, vincristine sulfate, etoposide, therapeutic conventional surgery, 3-dimensional conformal radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 3 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Alcohol Drinking, Drinking Behavior, At-risk Drinking, Cardiovascular Risk Factor, High Blood Pressure
Interventions: Alcohol Abstinence, Control arm; Behavioral · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 26 Years to 49 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Acute Respiratory Distress Syndrome (ARDS), Post Intensive Care Syndrome (PICS)
Interventions: An ICU admission and a temporally related ARDS diagnosis; Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 640,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 1,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Murfreesboro, Tennessee

Conditions: Breast Cancer
Interventions: MR spectroscopy; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Colon Cancer, Colorectal Cancer
Interventions: MRTX849, Irinotecan, Cetuximab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, Cancer, Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Interventions: Ara C, Mesna, Cyclophosphamide, TBI-Total Body Irradiation; Drug · Radiation
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cystic Fibrosis
Interventions: Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet [Nuzyra]; Drug
Lead sponsor: Paul Beringer; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Amyotrophic Lateral Sclerosis, Fasciculation
Interventions: FLX-787-ODT; Drug
Lead sponsor: Flex Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Traumatic Brain Injury
Interventions: FANCI; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Prostate Cancer
Interventions: Physical Therapy; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Solid Tumors
Interventions: rhEndostatin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 2 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2, Vehicle 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Mobile, Alabama • Los Angeles, California • Orange Park, Florida + 4 more

Conditions: Allergic Rhinitis
Interventions: Dymista Nasal Spray, Fluticasone propionate nasal spray; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 34 more

Conditions: Dry Eye Disease
Interventions: Propylene glycol-based eye drops; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Kansas City, Missouri • Norfolk, Virginia

Conditions: Transfusion Reactions
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Eating Disorders
Interventions: Dissonance-based eating disorder prevention program, Educational brochure; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Healthy Volunteers
Interventions: ABBV-243, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Decitabine, Dexamethasone, Palbociclib, Sorafenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mitral Valve Failure
Interventions: Edwards SAPIEN 3 transcatheter heart valve, ASHI INTECC Astato XS 20; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Detroit, Michigan + 3 more

Conditions: Hypercholesterolemia
Interventions: Simvastin, Computer-based decision support technology; Drug · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 45 Years to 70 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: System; Lupus Erythematosus
Interventions: Low Dose Mesenchymal Stem Cells (MSCs); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • Charleston, South Carolina

Conditions: Healthy Volunteer
Interventions: TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor

Reducing Cardiovascular Risks: The Role of Alcohol Use

An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Monitoring Response to Neoadjuvant Chemotherapy by the Use of Breast Proton MR Spectroscopy

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE

Pharmacokinetics of Omadacycline in Cystic Fibrosis

Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

Acute Neurobehavioral Program for Improving Functional Status After TBI

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Undergoing Prostatectomy

rhEndostatin Protein Involving Pediatric Patients With Cancer

CP-690-550 Ointment For Chronic Plaque Psoriasis

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease

Mild Pulmonary Function Changes With Transfusion

Effectiveness of a Dissonance-Based Eating Disorder Prevention Program (The Body Project II)

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation

Systematic Management of High Cholesterol Utilizing Computer Monitoring

Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects